Chad T. Campbell
Net Worth
Last updated:
What is Chad T. Campbell net worth?
The estimated net worth of Mr. Chad T. Campbell is at least $4,110,264 as of 17 Jul 2024. He owns shares worth $279,956 as insider, has earned $291,808 from insider trading and has received compensation worth at least $3,538,500 in AngioDynamics, Inc..
What is the salary of Chad T. Campbell?
Mr. Chad T. Campbell salary is $589,750 per year as Senior Vice President & GM of Vascular Access Global Bus. Unit in AngioDynamics, Inc..
How old is Chad T. Campbell?
Mr. Chad T. Campbell is 54 years old, born in 1971.
What stocks does Chad T. Campbell currently own?
As insider, Mr. Chad T. Campbell owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
AngioDynamics, Inc. (ANGO) | Senior Vice President & GM of Vascular Access Global Bus. Unit | 31,741 | $8.82 | $279,956 |
What does AngioDynamics, Inc. do?
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Chad T. Campbell insider trading
AngioDynamics, Inc.
Mr. Chad T. Campbell has made only one insider trade between 2019-2024, according to the Form 4 filled with the SEC.
As of 17 Jul 2024 he still owns at least 31,741 units of ANGO stock.
AngioDynamics key executives
AngioDynamics, Inc. executives and other stock owners filed with the SEC:
- Mr. Chad T. Campbell (54) Senior Vice President & GM of Vascular Access Global Bus. Unit
- Mr. David D. Helsel (61) Senior Vice President of Global Operations and R&D
- Mr. James C. Clemmer (61) Chief Executive Officer, Pres & Director
- Mr. Stephen A. Trowbridge (51) Executive Vice President & Chief Financial Officer
- Mr. Warren G. Nighan (56) Senior Vice President of Quality & Regulatory Affairs